All news

C4 Therapeutics director takes 4,618 shares over cash

Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash

C4 Therapeutics Director Donna Roy Grogan received 4,618 shares of the company's common stock on October 1, 2026, as compensation instead of cash director fees. The shares were valued at $3.14 each, aligning with the closing price on that date. Following this transaction, Grogan directly owns 79,471 common shares of C4 Therapeutics (NASDAQ:CCCC).

Read original source

CCCC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.